Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Summary Given its myeloid‐restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroF...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-06, Vol.193 (5), p.922-927
Main Authors: Bras, Anne E., Osmani, Zgjim, Haas, Valerie, Jongen‐Lavrencic, Mojca, te Marvelde, Jeroen G., Zwaan, C. Michel, Mejstrikova, Ester, Fernandez, Paula, Szczepanski, Tomasz, Orfao, Alberto, Dongen, Jacques J. M., Velden, Vincent H. J.
Format: Article
Language:English
Subjects:
acute leukaemia
ALL
AML
Flow cytometry
Haematological malignancy – Clinical
Hematology
immunophenotyping
Leukemia
Lymphocytes
myeloperoxidase
Peroxidase
Short Reports
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Given its myeloid‐restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte‐based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17210